Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Yuta, Ibuki"'
Autor:
Manato Ohsawa, Yoichi Hamai, Manabu Emi, Yuta Ibuki, Tomoaki Kurokawa, Toru Yoshikawa, Ryosuke Hirohata, Nao Kitasaki, Morihito Okada
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundNivolumab is approved in Japan as a second-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC) resistant to fluoropyrimidine and platinum-based drugs. It is also used in adjuvant and primary postoperative the
Externí odkaz:
https://doaj.org/article/166fbe0c6f0b465aa8f698d42453af1e
Autor:
Yuta Ibuki, Yukie Nishiyama, Yasuhiro Tsutani, Manabu Emi, Yoichi Hamai, Morihito Okada, Hidetoshi Tahara
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0231116 (2020)
BACKGROUND:MicroRNA (miR)s are promising diagnostic biomarkers of cancer. Recent next generation sequencer (NGS) studies have found that isoforms of micro RNA (isomiR) circulate in the bloodstream similarly to mature micro RNA (miR). We hypothesized
Externí odkaz:
https://doaj.org/article/42bab4ffa07c4bbcaa2c8743a5523ce6
Autor:
Manato Ohsawa, Yoichi Hamai, Manabu Emi, Yuta Ibuki, Tomoaki Kurokawa, Toru Yoshikawa, Ryosuke Hirohata, Nao Kitasaki, Morihito Okada
Publikováno v:
Surgery Today.
Autor:
Yoichi Hamai, Manabu Emi, Yuta Ibuki, Tomoaki Kurokawa, Toru Yoshikawa, Manato Ohsawa, Ryosuke Hirohata, Nao Kitasaki, Morihito Okada
Publikováno v:
OncoTargets and Therapy.
Yoichi Hamai, Manabu Emi, Yuta Ibuki, Tomoaki Kurokawa, Toru Yoshikawa, Manato Ohsawa, Ryosuke Hirohata, Nao Kitasaki, Morihito Okada Department of Surgical Oncology, Hiroshima University, Hiroshima, JapanCorrespondence: Yoichi Hamai, Department of S
Autor:
Manato, Ohsawa, Yoichi, Hamai, Manabu, Emi, Yuta, Ibuki, Tomoaki, Kurokawa, Toru, Yoshikawa, Ryosuke, Hirohata, Nao, Kitasaki, Morihito, Okada
Publikováno v:
Anticancer Research. 42:1499-1507
Trimodal therapy is frequently used for patients with locally advanced, resectable oesophageal cancer. However, it does not provide a satisfactory prognosis. The neutrophil-to-lymphocyte ratio (NLR) is an important indicator of patients' inflammatory
Autor:
YOICHI HAMAI, MANABU EMI, YUTA IBUKI, TOMOAKI KUROKAWA, TORU YOSHIKAWA, MANATO OHSAWA, RYOSUKE HIROHATA, NAO KITASAKI, MORIHITO OKADA
Publikováno v:
Anticancer research. 42(12)
To identify the correlations between theWe assessed the correlations between the maximum standardized uptake value (SUVmax) of primary tumors as reflected on preoperative FDG-PET images, the pathological features, and cancer recurrence in 124 patient
Publikováno v:
Transplantation.
Autor:
Manato Ohsawa, Yoichi Hamai, Manabu Emi, Yuta Ibuki, Tomoaki Kurokawa, Toru Yoshikawa, Ryosuke Hirohata, Nao Kitasaki, Morihito Okada
Publikováno v:
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 36(1)
Summary Accurate preoperative evaluation of lymph node (LN) metastasis is important for determining the treatment strategy for superficial esophageal cancer. Blood biomarkers, such as the neutrophil–lymphocyte, platelet–lymphocyte, and lymphocyte
Autor:
Manato Ohsawa, Yoichi Hamai, Manabu Emi, Yuta Ibuki, Tomoaki Kurokawa, Toru Yoshikawa, Ryosuke Hirohata, Nao Kitasaki, Morihito Okada
Background Accurate preoperative evaluation of lymph node (LN) metastasis is important for determining the treatment strategy for superficial esophageal cancer. There have been reports on the clinical significance of blood biomarkers, such as the neu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::623c853593552be39dfc86797f7d1268
https://doi.org/10.21203/rs.3.rs-1086029/v1
https://doi.org/10.21203/rs.3.rs-1086029/v1
Autor:
Yuta Ibuki, Yoichi Hamai, Toru Yoshikawa, Ikuno Nishibuchi, Morihito Okada, Yasushi Nagata, Yuji Murakami, Manabu Emi, Manato Ohsawa, Takaoki Furukawa, Tomoaki Kurokawa
Publikováno v:
Annals of Surgical Oncology. 27:4422-4430
The degree of metabolic activity in tumor cells can be determined by 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET). Associations between FDG uptake by primary tumors of locally advanced esophageal squamous cell carcinoma (ESCC) under